$9.19
1.77%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US2825591033
Symbol
ETNB

89bio Inc Stock price

$9.19
-0.15 1.61% 1M
+0.31 3.49% 6M
+1.37 17.52% YTD
-0.31 3.26% 1Y
+4.51 96.37% 3Y
-29.63 76.33% 5Y
-11.61 55.82% 10Y
-11.61 55.82% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.16 1.77%
ISIN
US2825591033
Symbol
ETNB
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$837.9m
Net debt
positive
Cash
$561.2m
Shares outstanding
148.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
83.7%
Return on Equity
-91.6%
ROCE
-82.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-467.1m | $-321.0m
EBIT
$-467.2m | $-338.0m
Net Income
$-450.2m | $-329.1m
Free Cash Flow
$-439.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-144.3% | 16.5%
EBIT
-144.3% | 12.1%
Net Income
-157.8% | 10.4%
Free Cash Flow
-165.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
$-3.0
Short interest
14.6%
Employees
93
Rev per Employee
$0.0
Show more

Is 89bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

89bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a 89bio Inc forecast:

14x Buy
82%
3x Hold
18%

Analyst Opinions

17 Analysts have issued a 89bio Inc forecast:

Buy
82%
Hold
18%

Financial data from 89bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
31% 31%
-
- Research and Development Expense 421 421
168% 168%
-
-467 -467
144% 144%
-
- Depreciation and Amortization 0.04 0.04
20% 20%
-
EBIT (Operating Income) EBIT -467 -467
144% 144%
-
Net Profit -450 -450
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about 89bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

89bio Inc Stock News

Neutral
GlobeNewsWire
6 days ago
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's management will participate in the following investor conferences during the month of September:
Positive
Seeking Alpha
23 days ago
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.
Positive
The Motley Fool
26 days ago
89bio (ETNB) Q2 R&D Jumps 131%
More 89bio Inc News

Company Profile

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

Head office United States
CEO Rohan Palekar
Employees 93
Founded 2018
Website www.89bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today